Medicare Enrolled

Dr. Ronald Andiman, M.D.

Neurology · Los Angeles, CA
Practice pattern: Clinical Cardiology — Primarily office-based clinical cardiology
Speaking/Promotional
8631 W 3RD ST # 531E, Los Angeles, CA 90048
3108557161
In practice since 2007 (19 years)
NPI: 1902936396 verify on NPPES ↗
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating. This page presents federal public records about Dr. Andiman from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Andiman? Request a correction or review of any data shown here. Provider portal →

What this data tells you about Dr. Andiman

Dr. Ronald Andiman is a neurology specialist in Los Angeles, CA, with 19 years of NPI registration. Based on federal Medicare data, Dr. Andiman performed 1,026 Medicare services across 602 unique beneficiaries.

Between the years covered by Open Payments, Dr. Andiman received a total of $57,733 from 71 pharmaceutical and/or device companies across 863 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in neurology. The majority of payments are for speaking programs and promotional activities, reflecting participation in industry-sponsored events. Patients may wish to discuss these relationships with their provider.

The Data Coverage level for Dr. Andiman is Very High — reflecting how much public federal data is available about this provider. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.

✓ 19 years in practice ▲ Top 31% volume in CA $57,733 industry payments

Medicare Practice Summary

Medicare Utilization ↗
1,026
Medicare services
Top 31% in CA for neurology
602
Unique beneficiaries
$98
Avg. Medicare payment
Medicare patients only (65+ / disabled) · How to read this →
~54 Medicare services per year of practice

Top procedures by volume

Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.

Procedure Volume Avg. paid Avg. submitted
Office visit, established patient (30-39 min)
A follow-up office visit for an existing patient lasting between 30 and 39 minutes. The visit involves medical evaluation and management of the patient's condition.
603 $99 $383
Prolonged office E/M service, first 15 minutes
This code is used for additional time spent by a physician beyond the maximum required time of a primary office or outpatient evaluation and management service. It is billed in 15-minute increments based on total time spent on the date of the primary service.
128 $27 $95
New patient office visit, complex (60-74 min) 127 $171 $660
Office visit, established patient, complex (40-54 min)
An office or outpatient visit for an existing patient lasting between 40 and 54 minutes. This level of service is determined by the total time spent on the date of the encounter.
87 $139 $484
Injection of anesthetic or steroid into upper neck and back of head nerve
An injection of an anesthetic agent and/or steroid into a nerve located in the upper neck and back of the head.
43 $61 $562
Trigger point injection, 3 or more muscles
Injection of medication into three or more specific muscle trigger points to relieve pain.
38 $28 $250
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.

Industry Payment Transparency

Open Payments through 2024 ↗
$57,733
Total received (2018-2024)
Avg $8,248/year across 7 years
Top 8% in CA for neurology
A higher payment rank reflects disclosed industry relationships (consulting, research, speaking) common among subspecialists — not wrongdoing.
71
Companies
863
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →

Payment profile

Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.

Speaking / Promotional
Speaker programs, honoraria, and industry-sponsored educational events
$37,588 (65.1%)
Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$15,805 (27.4%)
Consulting
Expert advisory fees, typically reflecting recognized clinical expertise
$4,340 (7.5%)

Payment trend by year

Annual totals from pharmaceutical and medical device companies.

2024
$1,156
2023
$3,066
2022
$13,211
2021
$15,878
2020
$15,080
2019
$2,731
2018
$6,612

Payments by company (2024)

Consulting
Speaking
Meals & Travel
Research
ABBVIE INC.
$211
PFIZER INC.
$202
Teva Pharmaceuticals USA, Inc.
$123
Novartis Pharmaceuticals Corporation
$114
SK Life Science, Inc.
$97
Lundbeck LLC
$89
Lilly USA, LLC
$75
Genentech USA, Inc.
$58
SCILEX PHARMACEUTICALS INC.
$41
Kyowa Kirin, Inc.
$38
Neurocrine Biosciences, Inc.
$33
Biogen, Inc.
$27
Grifols USA, LLC
$24
Otsuka America Pharmaceutical, Inc.
$23
Top 3 companies account for 46.4% of 2024 payments
All-time payments by company (2018-2024) ›
Allergan, Inc.
$15,183
Biohaven Pharmaceutical Holding Company Ltd.
$10,431
AbbVie Inc.
$6,777
Biohaven Pharmaceuticals, Inc.
$6,168
Promius Pharma LLC
$4,465
Amgen Inc.
$1,173
Novartis Pharmaceuticals Corporation
$985
GENZYME CORPORATION
$859
Amneal Pharmaceuticals LLC
$781
ABBVIE INC.
$717
Lilly USA, LLC
$707
Teva Pharmaceuticals USA, Inc.
$652
Lundbeck LLC
$613
Neurocrine Biosciences, Inc.
$524
UPSHER-SMITH LABORATORIES LLC
$515
UCB, Inc.
$496
PFIZER INC.
$459
SK Life Science, Inc.
$450
EMD Serono, Inc.
$431
US WorldMeds, LLC
$416
Kyowa Kirin, Inc.
$401
ACADIA Pharmaceuticals Inc
$383
Supernus Pharmaceuticals, Inc.
$369
Allergan Inc.
$330
Upsher-Smith Laboratories LLC
$327
Biogen, Inc.
$325
IMPEL PHARMACEUTICALS INC.
$313
Medtronic Vascular, Inc.
$166
Bausch Health US, LLC
$154
Alexion Pharmaceuticals, Inc.
$143
Avanir Pharmaceuticals, Inc.
$143
Sunovion Pharmaceuticals Inc.
$134
Acorda Therapeutics, Inc
$111
Genentech USA, Inc.
$92
Celgene Corporation
$89
Assertio Therapeutics, Inc.
$87
Currax Pharmaceuticals LLC
$82
EISAI INC.
$78
Egalet US Inc
$72
Eisai Inc.
$70
CSL Behring
$67
Impax Laboratories, Inc.
$61
Scilex Pharmaceuticals Inc.
$58
Greenwich Biosciences, Inc.
$55
Vertical Pharmaceuticals, LLC
$54
MDD US Operations, LLC
$51
Mallinckrodt Hospital Products Inc.
$50
Otsuka America Pharmaceutical, Inc.
$49
Janssen Pharmaceuticals, Inc
$48
Alnylam Pharmaceuticals Inc.
$46
MITSUBISHI TANABE PHARMA AMERICA, INC.
$46
E.R. Squibb & Sons, L.L.C.
$43
SCILEX PHARMACEUTICALS INC.
$41
Neurelis, Inc.
$36
ASSERTIO THERAPEUTICS, Inc.
$34
Sumitomo Pharma America, Inc.
$30
Mallinckrodt Enterprises LLC
$27
ARGENX US, INC.
$26
Ipsen Biopharmaceuticals, Inc
$25
Horizon Therapeutics plc
$25
Grifols USA, LLC
$24
Medtronic USA, Inc.
$23
Adamas Pharmaceuticals, Inc.
$20
Neuronetics, Inc.
$18
OPKO Pharmaceuticals, LLC
$17
Mylan Pharmaceuticals Inc.
$16
Abbott Laboratories
$16
Zyla Life Sciences, Inc.
$16
Avion Pharmaceuticals
$15
Bayer HealthCare Pharmaceuticals Inc.
$15
Arbor Pharmaceuticals, Inc.
$14
Top 3 companies account for 56.1% of all-time payments
Associated products mentioned in payments ›
ACTHAR · ACTIVA · AIMOVIG · AJOVY · AMPYRA · AMYVID · APOKYN · APTIOM · AUBAGIO · AUSTEDO · AVONEX · Aimovig · BOTOX · BOTOX THERAPEUTIC · Betaseron · Briviact · CAMBIA · COMIRNATY · CONTRAVE · Cambia · Dhivy · Dysport · EMGALITY · Epidiolex · Eprontia · Fycompa · GOCOVRI · Gamunex-C · Glatiramer Acetate · Gralise · Hizentra · INBRIJA · INGREZZA · Infinity DBS Pulse Generators · KESIMPTA · KYNMOBI · LEMTRADA · MAYZENT · MIGRANAL · MOUNJARO · MYOBLOC · Mavenclad · NAMZARIC · NEUROSTAR TMS THERAPY SYSTEM · NOURIANZ · NUEDEXTA · NUPLAZID · NURTEC ODT · Nourianz · ONGENTYS · ONPATTRO · ONZETRA XSAIL · OSMOLEX ER · OXTELLAR XR · Ocrevus · Ongentys · PAXLOVID · Ponvory · QUDEXY XR Topiramate Extended Release Capsules · QULIPTA · RADICAVA · RELEXXII · REXULTI · RYTARY · Rayaldee · Rebif · Reveal LINQ · SOLIRIS · SPRIX · Soliris · TECFIDERA · TOSYMRA · TOSYMRA SUMATRIPTAN NASAL SPRAY · TROKENDI XR · TYSABRI · Trudhesa · UBRELVY · UPLIZNA · VALTOCO · VUMERITY · VYEPTI · VYVGART HYTRULO · Vimpat · XENAZINE · Xadago · ZEMBRACE SYMTOUCH · ZEPOSIA · ZTLido · Zembrace · Zipsor
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →

The majority of payments (65%) are for speaking programs and promotional activities, which reflect participation in industry-sponsored educational or marketing events. This is common in neurology and does not inherently indicate bias, but patients may wish to be aware. Total industry engagement is in the top 8% for neurology in CA.

Looking for a neurology specialist in Los Angeles?
Compare neurologists in the Los Angeles area by procedure volume, costs, and industry payment transparency.
Browse neurologists nearby

Geographic Context

Neurologists within 10 mi
548
Per 100K population
5.6
County median income
$87,760
Nearest hospital
CEDARS-SINAI MEDICAL CENTER
0.0 mi

Data Sources

Provider Registry NPPES Weekly updates
Medicare Enrollment PECOS Monthly updates
Practice Data Medicare Util. Annual (CY lag)
Industry Payments Open Payments CY 2024
Disciplinary History — Not public N/A

This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This reflects how much public data is available about a provider. How we calculate this →

Summary

Dr. Andiman is a clinical cardiology specialist, with moderate Medicare volume, with speaking/promotional industry engagement in the top 8% of CA peers, with 19 years of NPI registration.

This summary is auto-generated from federal data, describing data availability and patterns. Read our methodology →

Frequently Asked Questions

Is Dr. Andiman experienced with office visit, established patient (30-39 min)?
Based on Medicare claims data, Dr. Andiman performed 603 office visit, established patient (30-39 min) services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Andiman receive payments from pharmaceutical companies?
Yes. Dr. Andiman received a total of $57,733 from 71 companies across 863 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Andiman's costs compare to other neurologists in Los Angeles?
Dr. Andiman's average Medicare payment per service is $98. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Andiman) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
About this page

All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.

This page is not medical advice, an endorsement, a recommendation, or a quality rating. Data Coverage reflects data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.

Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology

Data Disclaimer — Data sourced from the Centers for Medicare & Medicaid Services (CMS): National Plan and Provider Enumeration System (NPPES), Open Payments program, Medicare Provider Utilization and Payment Data, and Provider Enrollment & Certification data (PECOS). Published under the Freedom of Information Act (FOIA). This website is not affiliated with, endorsed by, or authorized by CMS, HHS, or the U.S. Government. Data may contain errors as reported to CMS by providers and reporting entities. Payments from industry are legal and do not indicate wrongdoing. Medicare data reflects only patients aged 65+ or those with qualifying disabilities. For corrections, contact CMS directly. This information does not constitute medical advice and should not be used as the sole basis for choosing a healthcare provider. Procedure descriptions use plain language and do not reference CPT® codes, which are copyrighted by the American Medical Association. Full methodology → · Report a data error → · Privacy policy →